Search Clinical Trials in the European Union

>2 years
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
1121-1140 of 1,743 trials

Neurodegenerative Disorders: Tau PET Imaging Study

We are exploring a new imaging method to identify early signs of neurodegenerative diseases in at-risk individuals. The study aims to understand how tau protein relates to cognitive changes and different types of dementia.

Neurodegenerative Diseases>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesNeurology

Advanced Sarcoma: NKG2D CAR-T Cell Therapy

We are testing a new type of immune cell therapy for children and young adults with advanced sarcoma. The study aims to see if this treatment is safe and effective in reducing tumor size.

Sarcoma>2 yearsSafety phase (I)No PlaceboInvestigational MedicinesOncology

Crohn’s Disease and Ulcerative Colitis: Tulisokibart Study

We are studying the long-term safety and effectiveness of tulisokibart in people with Crohn’s disease or ulcerative colitis. This research aims to see how well the treatment helps manage symptoms and achieve remission.

Crohn's DiseaseUlcerative Colitis>2 yearsConfirmation phase (III)>20 visitsPost-Trial Drug AccessInvestigational MedicinesGastroenterologyInternal Medicine

Glioblastoma Treatment: Optune with Pembrolizumab

We are testing whether adding pembrolizumab to Optune and temozolomide improves survival for newly diagnosed glioblastoma patients compared to a placebo. This study aims to understand the effectiveness and safety of this treatment combination.

Newly Diagnosed Glioblastoma>2 yearsConfirmation phase (III)Standard MedicinesOncology

Malignant Solid Tumors: GEN1057 Treatment

We are assessing the safety and potential effectiveness of GEN1057 for individuals with malignant solid tumors. This trial aims to see how well it works compared to current treatments.

Advanced Solid Tumors>2 yearsSafety phase (I)Oncology

Pleural Empyema: Surgery vs. Drainage

We are studying whether surgery is more effective than drainage for treating pleural empyema. This trial will help us understand the best approach for patients with this condition.

Pleural Empyema>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesInternal MedicinePulmonology

Advanced Lung Cancer: Eftilagimod Alfa with Pembrolizumab

We are studying a new drug, eftilagimod alfa, combined with pembrolizumab and chemotherapy for patients with advanced non-small cell lung cancer. The goal is to see if this combination works better than standard treatments.

Advanced Non-Small Cell Lung Cancer>2 yearsConfirmation phase (III)Investigational MedicinesCost ReimbursementPartially RemoteOncology

Skin Cancer Treatment: Nivolumab and Relatlimab Study

We are studying the effects of Nivolumab alone and in combination with Relatlimab for patients with advanced squamous cell carcinoma of the skin. This trial aims to find out which treatment may help control the disease better.

Locally Advanced/Metastatic Squamous Cell Carcinoma of the Skin>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesDermatologyOncology

Stroke Prevention: Low Dose Colchicine Study

We are investigating whether low dose colchicine can help prevent future strokes and other major vascular events in patients with a history of stroke due to atherosclerosis.

Cardiovascular Diseases>2 yearsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesCardiologyInternal Medicine

Palmo-Plantars Warts: HPV Vaccine Study

We are testing a nonavalent HPV vaccine to see if it helps people with difficult-to-treat warts on their hands and feet. The study aims to improve wart clearance, pain, and overall quality of life.

HPV Vaccine>2 yearsConfirmation phase (III)≤5 visitsStandard MedicinesPartially RemoteDermatologyInfectious Diseases

Lung Cancer Treatment: Nivolumab + Relatlimab with Chemotherapy

We are studying if a new combination treatment helps people with advanced non-small cell lung cancer live longer compared to standard treatment. This trial is for those whose cancer has spread or returned after previous treatment.

Advanced Non-Small Cell Lung Cancer>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementOncology

Osteoarthritis Behind the Kneecap: Nasal Cartilage Implantation

We are studying a new nasal cartilage treatment for people with osteoarthritis behind the kneecap to see if it improves recovery compared to standard care. The trial will also assess safety and how well the treatment works over time.

Knee OsteoarthritisPatellofemoral Osteoarthritis>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesInternal MedicineOrthopedics and Traumatology

Immunotherapy for Advanced Cancer: Standard vs. Reduced Dose

We are comparing standard immunotherapy treatment with a less frequent dosing schedule for patients with advanced cancer. The goal is to see if the reduced dose is just as effective and to evaluate its impact on quality of life and safety.

Advanced or Metastatic Cancer>2 yearsConfirmation phase (III)11-15 visitsNo PlaceboStandard MedicinesOncology

Triple-Negative Breast Cancer: Ceralasertib with Durvalumab and Nab-Paclitaxel

We are studying a new treatment approach for patients with advanced triple-negative breast cancer who have relapsed after prior therapies. This trial aims to see if combining ceralasertib with other medications can improve their response to treatment.

Advanced Triple Negative Breast Cancer>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesOncology

Metastatic Colorectal Cancer: Trifluridine/Tipiracil with Panitumumab vs. Bevacizumab

We are studying two treatment combinations to find out which one works better for people with metastatic colorectal cancer. The trial also looks at safety and how treatments affect patients' quality of life.

Metastatic Colorectal Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesPartially RemoteOncology

Prostate Cancer: 225Ac-PSMA I&T Treatment

We are testing a new radioactive treatment for men with prostate cancer. This study aims to evaluate its safety and how well it works.

Metastatic Prostate Cancer>2 yearsSafety phase (I)Oncology

Breast Cancer Prevention: Denosumab for Women with BRCA1 Mutation

We are studying whether Denosumab can help prevent breast cancer in women carrying a BRCA1 mutation. This trial compares its effects to a placebo to see if it reduces cancer risk.

Breast Cancer Prevention in BRCA1 Mutation Carriers>2 yearsConfirmation phase (III)11-15 visitsStandard MedicinesPartially RemoteHematologyOncology

IDH1/IDH2-Mutant Glioma: Vorasidenib with Temozolomide

We are studying the safety and effectiveness of a new drug, vorasidenib, combined with temozolomide for patients with IDH1- or IDH2-mutant gliomas. This research aims to see if this combination can improve treatment outcomes.

IDH1-mutant GliomaIDH2-mutant Glioma>2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Sickle Cell Disease: Hydroxycarbamide Tablets for Children

We are studying the effects of a twice-daily dose of Hydroxycarbamide in children with sickle cell disease. This trial aims to evaluate its safety, effectiveness, and how well children tolerate the treatment.

Sickle Cell Disease>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteHematologyPediatrics

Karonudib for Blood Cancers: Phase 1 Study

We are evaluating the safety and tolerability of Karonudib in patients with advanced blood cancers like Acute Myeloid Leukemia and Multiple Myeloma. This study aims to find the best dose and understand how well it works with other cancer treatments.

Blood Cancers>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesHematologyOncology